AUS
NZ
UK
CA
USA
IND
ImpediMed Limited (ASX:IPD), an Australian medical technology firm specializing in bioimpedance spectroscopy, has informed the market that more than 20 million unquoted equity securities have expired following the failure to meet vesting conditions by 30 June 2026. Specifically, 11,642,750 options and 8,529,911 performance rights ceased after their attached conditions were unmet or became impossible to satisfy by the deadline. This update, submitted on 3 July 2026 via an Appendix 3H form, confirms that no compensation was provided to holders upon cessation. Stakeholders may be closely monitoring the implications of this lapse on the company’s executive and employee remuneration framework going forward.
Key Points
- Company: ImpediMed Limited (ASX:IPD)
- 11,642,750 unquoted options (IPDAAB) lapsed on 30 June 2026 due to unmet performance or vesting criteria
- 8,529,911 performance rights (IPDAA) also expired on 30 June 2026 for the same reasons
- No consideration was paid to holders for either class of expired securities
- Post-lapse, IPD’s ordinary shares total 3,659,805,353, with 1,800,000,000 quoted options (IPDO) expiring 31 March 2027 still outstanding
- Investors should observe for any forthcoming incentive grants or updated remuneration disclosures following these lapses
Details Behind the Expiry of 11.6 Million Options on 30 June 2026
The largest portion of expired securities comprises 11,642,750 unquoted options under the ASX code IPDAAB, which have varying expiry dates and exercise prices. These options expired on 30 June 2026 because their vesting conditions were not met or became impossible to fulfill by that date. The company’s Appendix 3H filing confirms no payments were made to option holders related to their lapse.
Such options are commonly granted to executives, senior managers, or eligible employees as part of long-term incentives. Vesting conditions often include financial targets, share price milestones, or continued employment requirements. The announcement does not specify which conditions failed, so investors seeking further details may refer to ImpediMed’s latest remuneration report or equity plan documents. It is clear, however, that these options will not convert into ordinary shares and have been permanently removed from the register.
Extinction of 8.5 Million Performance Rights (IPDAA) on 30 June 2026
In addition to the options, ImpediMed reported that 8,529,911 performance rights (IPDAA) also expired on 30 June 2026 due to unmet vesting conditions. Similar to the options, no consideration was paid to holders upon expiration.
Performance rights are commonly used as long-term incentives and typically convert into ordinary shares on a one-for-one basis once performance criteria are satisfied. The lapse of nearly 8.53 million performance rights reduces the potential future dilution for existing shareholders. For context, ImpediMed’s ordinary shares on issue now total 3,659,805,353, meaning the expired performance rights represented approximately 0.23% of the current share count — a factor investors may consider when assessing dilution that did not occur.
Updated Capital Structure Following Security Expirations
Following these expirations, the Appendix 3H filing outlines ImpediMed’s capital structure. The company has 3,659,805,353 fully paid ordinary shares (IPD) and 1,800,000,000 quoted options (IPDO) expiring 31 March 2027. These quoted options represent a significant potential source of equity if exercised before expiry.
On the unquoted side, the register includes 1,800,000,000 unquoted options (IPDAD) expiring 31 December 2027 with an exercise price of $0.015, 18,737,805 warrants (IPDAB), 39,402,250 remaining IPDAAB options after the lapse of 11,642,750, and 7,335,466 remaining IPDAA performance rights following the lapse of 8,529,911. The company notes that issued capital figures are automatically generated and may not fully reflect the current position if other ASX forms are being processed concurrently.
Remaining Active IPDAAB Options and IPDAA Performance Rights
Despite the substantial lapse, both IPDAAB options and IPDAA performance rights classes retain active securities. Post 30 June 2026, 39,402,250 IPDAAB options and 7,335,466 IPDAA performance rights remain outstanding. This indicates that only those securities linked to unmet conditions expired, while others remain subject to ongoing vesting criteria.
The existence of these remaining securities suggests that parts of ImpediMed’s incentive plans continue to function, with future vesting events possible depending on performance and employment conditions. Investors and analysts should consider both expired and surviving tranches when evaluating potential impacts on share count and dilution in upcoming periods.
Focus on 1.8 Billion IPDO Quoted Options Expiring in March 2027
Separately, ImpediMed holds 1,800,000,000 quoted options (IPDO) expiring 31 March 2027, distinct from the unquoted employee incentives discussed. These options will be a key focus for the market in coming months. If exercised, they could provide a significant capital inflow, although the exercise price was not disclosed in this filing.
The combined presence of 1.8 billion quoted options and 1.8 billion unquoted options (IPDAD) expiring December 2027 at $0.015 means ImpediMed’s fully diluted capital base could expand substantially from the current 3.66 billion ordinary shares, depending on exercise outcomes. Investors should monitor future company announcements for developments regarding these large option tranches, as their exercise or expiry will directly affect shareholder equity and the company’s funding position.
No Compensation Paid to Holders Upon Security Expiration
The Appendix 3H filing explicitly states that no consideration was paid to holders of the lapsed options or performance rights. This aligns with standard practice where unexercised or unvested incentive securities expire without payment if conditions are unmet. This outcome does not impact the company’s cash position, as no funds are required to retire these securities.
Legally, the Appendix 3H is the ASX-required form for reporting cessation of previously issued securities, detailing the security type, number ceased, reason, and date, alongside an updated issued capital table. ImpediMed complied with these disclosure requirements in its 3 July 2026 filing, ensuring transparency regarding capital structure changes.
Reduced Potential Dilution for Ordinary Shareholders
The lapse of over 20 million incentive securities marginally lowers potential dilution for ordinary shareholders compared to if all options and performance rights had vested and been exercised. Although approximately 20.17 million securities lapsed, this number is modest relative to the 3.66 billion shares outstanding, yet it removes a future source of share issuance that would have slightly diluted shareholders’ interests.
More significant dilution risks stem from the large unquoted option tranche (IPDAD) of 1.8 billion options at $0.015 expiring December 2027 and the 1.8 billion quoted IPDO options expiring March 2027. These larger pools dominate the near-term capital structure considerations. The recent lapse of incentive securities, while relevant to remuneration governance, has a lesser impact on shareholder dilution analysis.
Insights into Incentive Plan Governance and Unvested Securities
The expiry of options and performance rights linked to unmet conditions underscores the performance-based nature of ImpediMed’s executive and employee incentive programs. Long-term incentives typically require satisfaction of time-based and performance-based criteria before vesting. Failure to meet such hurdles results in expiry, aligning executive outcomes with shareholder returns.
The announcement does not disclose the specific unmet conditions or identify holders of the lapsed securities. Shareholders seeking comprehensive context—including performance metrics, measurement methods, and timeframes—should consult ImpediMed’s annual or remuneration reports. Future incentive grants may incorporate revised performance criteria aligned with the company’s strategic goals. Investors will likely watch for disclosures of new long-term incentive arrangements in upcoming communications.
Implications of the Updated Capital Table for Share Registry
The updated capital table reflects a moderately complex register with various funding and incentive instruments issued over time. With 3,659,805,353 ordinary shares, 1.8 billion quoted options, 1.8 billion unquoted options, 18.7 million warrants, approximately 39.4 million remaining unquoted options, and 7.3 million remaining performance rights, the fully diluted potential capital base is considerable. The company did not indicate any plans to simplify or consolidate its capital structure in this filing.
For investors and analysts modeling ImpediMed’s financials, the updated capital table is critical for calculating diluted share counts. The lapse of these securities is generally viewed as an administrative matter rather than a price-sensitive event, so immediate share price impact was unclear. The next major capital structure milestone will be developments related to the two large option tranches expiring in 2027. Market participants should monitor forthcoming ImpediMed releases for updates.
